Research programme: cannabinoid-based therapeutics - InMed Pharmaceuticals

Drug Profile

Research programme: cannabinoid-based therapeutics - InMed Pharmaceuticals

Alternative Names: CTI-091; Delta-9-tetrahydrocannabinol - InMed Pharmaceuticals; Dronabinol - InMed Pharmaceuticals; INM-405

Latest Information Update: 25 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cannabis Technologies
  • Developer InMed Pharmaceuticals; University of British Columbia
  • Class Analgesics; Anti-inflammatories; Antirheumatics; Cannabinoids
  • Mechanism of Action Gene expression modulators; Immunomodulators; Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Arthritis; Inflammation; Joint disorders; Musculoskeletal pain; Pain

Most Recent Events

  • 17 Oct 2017 Pharmacodynamics and safety data from a preclinical trial in Pain released by InMed Pharmaceuticals
  • 03 Oct 2017 InMed Pharmaceuticals files a provisional patent application for INM 405 and other cannabinoid-based topical therapies for Pain in USA
  • 26 Sep 2016 Pharmacodynamics data from a preclinical trial in Pain presented at the 16th World Congress on Pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top